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Abstract
Background: Sulfur mustard (SM) is a chemical warfare agent that can cause serious pulmonary complications.
This study was designed to determine serum highly sensitive C-reactive protein (hs-CRP) and evaluate its
correlation with lung function parameters in patients with chronic obstructive pulmonary disease (COPD) due
to SM poisoning.Methods: Fifty consecutive SM patients with stable COPD and a mean age 46.3+ 9.18 years
were enrolled in this cross sectional study. Thirty healthymenwere selected as controls. Lung function parameters
were evaluated. Serum hs-CRP by immunoturbidometry assay was measured in both the patients and controls.
Results: In the case group, the mean forced expiratory volume in one second (FEV1) was 2.14 + 0.76 L
(58.98%+ 17.51% predicted). The mean serum hs-CRPwas 9.4+ 6.78 SD and 3.9+ 1.92 SDmg/L in the cases
and controls, respectively, with significant statistical differences (p< .001). Therewas negative correlation between
the serum hs-CRP and FEV1 levels (p¼ .01). The serum hs-CRP levels were also correlated with Global Initiative
for Chronic Obstructive Lung disease (GOLD) stages (r¼ .45, p < .001).Conclusions:Our findings suggest that
the serum hs-CRP level is increased in SM patients with COPD and may have a direct correlation with disease
severity. It may then be used as a marker for the severity of COPD in patients with SM poisoning.
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Introduction
Sulfur mustard (SM) is a chemical warfare agent that
was used in large scale during the World War I and in
the Iran–Iraq conflict between 1983 and 1988.1 During
the Iran–Iraq war, over 100,000 Iranians were exposed
to sulfurmustard, of which 45,000 patients are now suf-
fering from complications of SM poisoning.2 SM is a
potent, toxic, alkylating agent that is able to cause
serious ocular, neurologic, cutaneous, bone marrow,
immunodeficiency, and pulmonary complications.1
Respiratory problems are the most common late
complications of SM poisoning in the veterans.3-5
Ghanei et al. reported that chronic bronchitis is the
most frequent late respiratory disease among Iranians
exposed to mustard gas.6 A unique form of chronic
obstructive pulmonary disease (COPD), named
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‘‘Mustard Lung,’’ was proposed in patients with late
respiratory complications of SM poisoning.3
As COPD is a systemic inflammatory condition,
inflammatory markers such as C-reactive protein
(CRP), interleukin 6, and tumor necrosis factor a
(TNF-a) have important roles in its pathogenesis.
Highly sensitive C-reactive protein (hs-CRP) is one
of the important inflammatory markers and is mainly
synthesized by hepatocytes during inflammatory
reactions.7 In the last decade, concern has grown
about significant correlations of hs-CRP with myocar-
dial infarction, unstable angina, and stroke.8 It is now
believed that hs-CRP levels also relate to the presence
of airflow obstruction.7,8 Pinto-Plata et al.8 and
Ridker9 found that hs-CRP levels are elevated in
COPD patients without clinically relevant ischemic
heart disease, independent of cigarette smoking. The
prevalence of increased hs-CRP in COPD patients has
been examined in the National Health and Nutrition
Examination Survey III, where 41% of patients with
moderate COPD had hs-CRP levels >3 mg/L, and
6% had levels >10 mg/L. In comparison, 52% of
patients with severe COPD had hs-CRP levels
>3 mg/L and 23% had levels >10 mg/L.10,11 Dahl
et al.12 suggested that hs-CRP is a strong and
independent predictor of future COPD outcomes in
individuals with airway obstruction. Hs-CRP is higher
in patients with low forced expiratory volume in one
second (FEV1) and in smokers.13 In addition, hs-CRP
is elevated in stable and exacerbated states of
COPD.14,15 It is possible that elevated levels of hs-
CRP are also a predictor of cardiovascular disease
in COPD patients.16
The present study is the first, of which we are aware,
that was designed to determine serum hs-CRP and
evaluate its correlation with lung function parameters
in patients with COPD due to SM poisoning.
Materials and methods
Subjects
The current cross-sectional study was performed on
the chemical war gassed veterans with stable COPD
aged 37 to 65 years attending the pulmonary clinic
of Ghaem hospital, in Mashhad, Iran between April
and September 2008. All patients had validated docu-
ments of SM gas exposure and suffered from compli-
cations of SM poisoning. The time since SM exposure
ranged from 19 to 23 years. All studied subjects were
non-smoker males. Patients with all levels of severity
of COPD were included in the study if they had a
post-bronchodilator FEV1/FVC (forced vital capac-
ity) < 0.7 after 400 mg of inhaled albuterol, according
to the definition of the American Thoracic Society
(ATS).17 The patients were excluded if their FEV1
increased more than 12% and 200 mL after broncho-
dilator; or those who had asthma, bronchiectasis,
tuberculosis, active pulmonary infections, cardiovas-
cular diseases, cerebrovascular diseases, diabetes
mellitus, or other confounding inflammatory diseases,
such as malignancy, arthritis, connective tissue dis-
eases, and inflammatory bowel disease or if they had
exacerbation of disease or hospitalization during the
last 2 months. Also those patients who had taken
aspirin and statins were excluded. Thirty healthy
non-smoker men with no history of pulmonary, cardi-
ovascular, or inflammatory disease were enrolled as a
control group for hs-CRP analysis. Their age and
weight were matched with cases.
Interview and physical examination
All subjects were visited by one chest physician. In
addition to a detailed physical examination, a question-
naire was completed by physician for each patient that
included the following items: age, duration of disease,
date of sulfur mustard exposure, current inhaled
corticosteroid therapy, and home oxygen therapy.
Weight (with clothes on) and height (without shoes)
were measured for each participant, and body mass
index (BMI) was calculated as weight (kg) divided
by height (m) squared. All subjects completed the St
George’s Respiratory questionnaire (SGRQ) on health
impairment; while sited at a desk in a quiet area free
from distraction.18 Using the SGRQ, the symptoms,
activity, impact, and total scores were calculated for
each patient with an Excel-based scoring calculator.18
Lung function tests
Forced expiratory volume in one second, FVC, and
FEV1/FVC were measured by standard spirometric
techniques (Multi-Functional SpirometerHI-801,Chest
M.I., Inc, Tokyo, Japan) and the values were expressed
as a percentage of the predicted values. The best of three
consecutive recordings of spirometry was used. The
severity of COPDwas assessed using the Global Initia-
tive for Chronic Obstructive Lung disease (GOLD)
guidelines.19 Dyspnea was assessed by the Modified
Medical ResearchCouncil (MMRC) scale,20whichwas
graded from0 to 4 scales according to the patient’s com-
plaint. Patients performed the 6-min walk test (6MWT)
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according to the ATS guidelines21 in a 30-m flat and
straight indoor corridor with marking every 3 m. The
body mass index, obstruction, dyspnea, and exercise
capacity (BODE) index was calculated in all patients
with total possible values range from 0 to 10.20
Blood samples
Blood samples were obtained in non-fasting condi-
tions and at rest. Serum hs-CRP was measured by
immunoturbidometry assay (Roche Diagnostics,
Mannheim, Germany) and an auto analyzer (Lysis,
Milan, Italy), with a normal value defined as less than
5 mg/L. The maximum interassay and intra-assay
coefficient of variation for the range of hs-CRP con-
centrations evaluated were 3.5%. The lower limit of
detection was 0.1 mg/L. The samples were identified
by bar code, so that samples from controls and COPD
patients were randomly distributed among the assay
plates. Arterial blood gases were measured by a blood
gas analyzer (AVL 995; AVL Scientific Corporation,
Roswell, GA., USA). The study was approved by the
ethics committee of the Mashhad University of
Medical Sciences (MUMS). All patients gave
informed consent.
Statistical analysis
The data were analyzed using statistical package for
social sciences (SPSS, version 14.0). The variables
are presented as percentages and means + SDs.
Descriptive statistics were used to summarize the
demographic characteristics of the case and control
groups. The normality of continuous variables was
checked using the one sample Kolmogorov-Smirnov
test. For continuous and categorical variables, inde-
pendent student’s t tests and chi-square tests were
used to evaluate the statistical significance of any
difference or relationship between parameters,
respectively. Pearson and Spearman correlation coef-
ficients were calculated. p Values less than .05 were
considered significant.
Results
A total of 50 consecutive male patients were included
in this study. The mean age of the patients was 46.3+
9.18 years with BMI of 27.32+ 3.30 kg/m2. The con-
trols were matched by age and BMI to the patients
(47.8 + 7.9 years and 27.2+ 2.1, respectively).
The majority of patients were in GOLD stages II
and III (54% and 24%, respectively). Twenty-one
patients (42%) were taking inhaled corticosteroid and
9 (18%) were on home oxygen therapy. The demo-
graphic and clinical characteristics of the patients are
summarized in Table 1. The mean serum hs-CRP lev-
els were significantly higher in the patients than in the
controls (9.4+ 6.78 SD versus 3.9+1.92 SD mg/L,
p < .001). Out of 50 patients in the case group, 32
(64%) had high serum hs-CRP levels (5 mg/L).
The correlations of hs-CRP with the potential para-
meters of COPD severity in the patients were exam-
ined and are shown in Table 2. There was a
correlation between the GOLD stages and hs-CRP
(r ¼ .45, p ¼ .001) as illustrated in Figure 1. Also,
other correlations were found between hs-CRP and
the following parameters: FEV1 (r ¼ –.32, p ¼ .01;
Figure 2), FEV1 percent predicted (r ¼ –.36, p ¼
.010), and PaCO2 (r ¼ .37, p ¼ .009).
As shown in Table 3, higher GOLD stages had
higher frequencies of patients with elevated hs-CRP
levels (p ¼ .041). The mean hs-CRP levels were not
statistically different between patients on inhaled
Table 1. Clinical and pathophysiological parameters of 50




Age (yrs)* 46.3 + 9.18
Duration of disease (yrs)* 17.00 + 6.00
FEV1 (L)* 2.14 + 0.76
FEV1 (% Pred.)* 58.98 + 17.51
FEV1/FVC* 62.14 + 9.70





6MWD (m)* 327.8 + 86.96
BMI* 27.32 + 3.30
PaO2 (mm Hg)* 75.1 + 12.00
SaO2 (%)* 94.03 + 3.45
PaCO2(mm Hg)* 55.37 + 9.50




hs-CRP (mg/l)* 9.4 + 6.78
*The data are presented as the mean+ SD. FEV1, forced expira-
tory volume in one second; FVC: forced vital capacity; GOLD:
Global Initiative for Chronic Obstructive Lung Disease; 6MWD:
6-min walk distance; BMI: body mass index; PaO2: arterial oxygen
tension; SaO2: arterial O2 saturation; PaCO2: arterial carbon
dioxide tension; SGRQ: Saint George’s Respiratory Questionnaire;
hs-CRP: highly sensitive C-reactive protein.
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steroid therapy and those who were not (9.1 + 7.0
versus 8.6 + 6.9, p¼0.64). Additionally, there was
negative correlation between BMI and the duration
of disease (r ¼ –.28, p ¼ .04).
Discussion
To our knowledge, the present study was the first to
evaluate the relationship between hs-CRP as an
inflammatory marker and clinical and paraclinical
severity factors in patients with respiratory complica-
tion of SM poisoning. The important findings of this
study were significant correlations of hs-CRP with the
GOLD stages, FEV1, and PaCO2 in these patients.
In this study, we found that, despite the exclusion
of smoking, cardiovascular diseases, infections, and
other important inflammatory conditions, hs-CRP
levels are raised in SM patients and that significant
differences in the mean hs-CRP levels exist between
patients and controls. These findings are similar to
those of de Torres and colleagues7 in COPD patients.
In addition to COPD, which is the most frequent
clinical pulmonary complication of SM exposure,3 a
recent pathologic study of surgical lung biopsies
revealed that bronchiolar disease is the main patholo-
gic finding in this group of patients.22 This study22
Table 2. Correlation of hs-CRP with other parameters





GOLD stage .45 .001
BMI .27 .056
Duration of disease .082 .573
FEV 1 –.32 .010




6 MWD –.14 .330
BODE index .07 .613
Total SGRQ score –.2 .85
Hs-CRP, highly sensitive C-reactive protein; GOLD, Global Initia-
tive for Chronic Obstructive Lung Disease; BMI, body mass index;
FEV1, forced expiratory volume in one second; PaCO2, arterial
carbon dioxide tension; PaO2, arterial oxygen tension; MMRC,
Modified Medical Research Council; 6MWD, 6-min walk distance;
BODE, body mass index, obstruction, dyspnea and exercise
capacity, SGRQ, ST George Respiratory Questionnaire.
Figure 1. Correlation between highly sensitive C-reactive
protein (hs-CRP) and global initiative for chronic








R Sq Linear = 0.111
Figure 2. Correlation between forced expiratory volume
(FEV) and highly sensitive C-reactive protein (hs-CRP).
Table 3. The relation between GOLD stages and serum







1 5 (71.4%) 2 (28.6%) 7 (100%)
2 11 (40.7%) 16 (59.3%) 27 (100%)
3 2 (16.7%) 10 (83.3%) 12 (100%)
4 0 (0.0%) 4 (100.0%) 4 (100.0%)
Total 18 (36.0%) 32 (64.0%) 50 (100.0%)
GOLD, Global Initiative for Chronic Obstructive Lung Disease;
hs-CRP, highly sensitive C-reactive protein.
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showed that obliterative bronchiolitis (or features that
strongly suggest its presence) and varying degrees of
bronchiolar inflammation are the most common
bronchiolar pathologic findings in this population.
Our finding that 64% of patients had high hs-CRP
levels, taken together with this previous research,
implies that inflammation plays an important role in
patients with respiratory complication of SM poison-
ing, especially in more advanced stages.
In the present study, the hs-CRP levels were
inversely correlated with FEV1 and FEV1 percent
predicted and directly correlated with the GOLD stage
and PaCO2. In the de Torres et al. study of stable COPD
patients,7 the hs-CRP levels were mainly correlated
with physiological parameters, such as FEV1, FVC,
inspiratory capacity (IC) to total lung capacity (TLC)
IC/TLC, 6MWT, PaO2, and BMI, and other factors
such as the BODE index and GOLD stages. Our results
demonstrated that, as in other COPD patients, the
hs-CRP levels increased with progression of COPD
severity in SM patients. Hs-CRP may have an impor-
tant role as an inflammatory marker of disease severity
in mustard lung patients as it does in other COPD
patients. Gan and colleagues13,14 were the first to note
the importance of high CRP levels in COPD patients
who actively smoked, had reduced lung function, or
had stable COPD. It has also been reported that COPD
patients have higher levels of CRP independent of
cardiovascular risk factors.7,8 Broekhuizen et al.23
found that hs-CRP was a marker of impaired energy
metabolism, functional capacity, and distress in 102
severe COPD patients. Dahl et al.12 have proposed that
plasma CRP may not only be useful in assessing
inflammation during the course of COPD but may also
be a marker for monitoring inflammation during
COPD treatment. The present study confirmed previ-
ous studies regarding the possible role of inflammation
in this group of COPD patients.7,8,13
In this study, 87% of patients were in moderate and
severe stages of COPD according to GOLD staging,
and 56% had a BODE index 3. In light of the mean
long interval of 17 years since SM exposure, it seems
that respiratory complication of SM has a progressive
nature even after exposure has ceased. This is also
reflected in the BMI of patients, which decreased
correlation with the duration of the disease. The mean
6MWD in our study was 327.80+ 86.96 m. Teramoto
et al.24 established the normal reference value of 592 m
in healthy Asian men. Therefore, it demonstrates a sig-
nificant functional disability in this group of patients.
This finding was consistent with Broekhuizen et al.23
who reported the functional impairments of patients
due to the inflammatory basis of their disease. Further-
more, a comparison of total SGRQ scores of SM
patients with normal subjects’ values18 revealed a sig-
nificant impairment in the quality of life for these
patients. These results were consistent with that of
Attaran and colleagues25 who reported that distur-
bances in the quality of life for SM patients are a
serious problem.
We did not find any significant differences in
the hs-CRP levels between patients on inhaled corti-
costeroid therapy compared to those who were not.
This may be due to the low compliance of patients,
small sample size of subjects, or the suboptimal use
of drugs. This finding is similar to that of de Torres
et al.7 who found that patients on inhaled corticoster-
oid therapy had lower hs-CRP levels, although this
was not statistically significant.
However, we found elevated hs-CRP levels that
were independent of any specific risk factors in SM
patients. A large series of prospective epidemiologi-
cal studies have convincingly demonstrated that CRP,
when measured with high sensitivity assays, strongly
and independently predicts the risk of myocardial
infarction, stroke, peripheral arterial disease, and
sudden cardiac death among apparently healthy indi-
viduals.26 Therefore, paying more attention to this
matter may be necessary.
This study has several limitations. The first is the
absence of other COPD patients (such as those with
COPD due to smoking) as a control group. Second,
our small sample size may limit the interpretation of
our results.
Conclusion
The present study demonstrates that chronic lung dis-
ease in patients with respiratory complication of SM
poisoning is associated with systemic inflammation
and that level of inflammatory markers (hs-CRP) is
correlated with the severity of airway disease. Serum
hs-CRP significantly correlates with GOLD, FEV1,
FEV1 percent predicted, and PaCO2. In these patients,
as in COPD, hs-CRP may play a significant role in
disease severity and could be used as a marker of
severity in addition to other clinically important
prognostic factors.
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